scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10067-010-1406-6 |
P698 | PubMed publication ID | 20204668 |
P2093 | author name string | Akihiro Sudo | |
Kusuki Nishioka | |||
Atsumasa Uchida | |||
Masahiro Hasegawa | |||
Hiroshi Oka | |||
Hiroki Wakabayashi | |||
P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 | ||
Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis | Q35552614 | ||
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept | Q35555131 | ||
Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values | Q35760044 | ||
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? | Q35954640 | ||
Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis pat | Q35954667 | ||
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status | Q36772881 | ||
Efficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab | Q37209761 | ||
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate | Q47784405 | ||
The NICE reappraisal of biologics in 2005: what rheumatologists need to know | Q57995952 | ||
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM) | Q58204927 | ||
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial | Q74455184 | ||
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis | Q77341367 | ||
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis | Q82690906 | ||
Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? | Q83172291 | ||
P433 | issue | 6 | |
P921 | main subject | rheumatoid arthritis | Q187255 |
methotrexate | Q422232 | ||
P304 | page(s) | 671-675 | |
P577 | publication date | 2010-03-04 | |
P1433 | published in | Clinical Rheumatology | Q15754927 |
P1476 | title | Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis | |
P478 | volume | 29 |
Q37345837 | Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials |
Q85522624 | Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure |
Q51417238 | Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis. |
Search more.